Pharmaceuticals

AstraZeneca has opened its newest global strategic research and development center in Kendall Square, Cambridge, Massachusetts, part of a more than $1 billion investment in the state that will expand its Massachusetts workforce by over 50 percent in the coming years. The 570,000 square foot, 18 story site at 290 Binney Street will house nearly 2,000 researchers and scientists alongside the company's genomic medicine site at 100 Binney Street, and includes ten floors of interconnecting laboratories integrating robotics, continuous automation and agentic AI. The scientists will work on AstraZeneca's oncology, cell therapy, chronic disease and rare disease pipeline, targeting conditions such as COPD, obesity and metabolic disease, breast cancer and rare diseases, while pursuing future innovation in cell therapy and biologics to fuel growth beyond 2030. The Massachusetts investment sits within AstraZeneca's broader $50 billion US investment, and the new site joins its other US-based global strategic research center in Gaithersburg, Maryland, as part of a coast-to-coast footprint of 24 R&D, manufacturing, commercial and corporate sites. Chief Executive Officer Pascal Soriot said Kendall Square is a leading innovation ecosystem and one of the key locations where AstraZeneca will discover the next generation of scientific breakthroughs, while Massachusetts Governor Maura Healey called the investment a major vote of confidence in the state.

Novartis entered a licensing and option agreement with China-based Abogen Biosciences, giving the Swiss pharma giant exclusive worldwide rights to Abogen's lead candidate ABO2203 and options to license additional programs built on Abogen's proprietary RNA platform. Under the agreement, Abogen will receive an upfront payment of $575 million and is eligible to receive up to approximately $7.2 billion in potential milestone payments if all options covering additional programs are exercised and the specified development, regulatory and commercial milestones are achieved, plus royalties on future product sales. ABO2203 is an investigational messenger RNA-encoded CD19xCD3 T-cell engager being developed for autoimmune diseases, designed to reset B cells by directing endogenous production of T-cell engagers in vivo. The transaction remains subject to customary closing conditions, including required regulatory clearances. The deal comes as Novartis faces generic competition for Entresto and Promacta and back-to-back pipeline setbacks, including the late-stage failure of pelacarsen and the HARBOR study of del-desiran in myotonic dystrophy type 1.

Summit Therapeutics has signed a clinical collaboration with AstraZeneca and its Japan-based partner Daiichi Sankyo to evaluate ivonescimab in combination with the antibody-drug conjugate Datroway, also known as datopotamab deruxtecan, across multiple solid tumors including breast and lung cancers. The collaboration is expected to initially focus on a phase III study in first-line triple-negative breast cancer, expanding ivonescimab's development into a new tumor type. Under the agreement, each company will supply its respective drug, AstraZeneca or Daiichi will sponsor the planned studies, and the companies will share study costs while retaining development and commercial rights to their own therapies. The Datroway collaboration builds on the larger deal between AstraZeneca and Summit announced in the last week, under which AstraZeneca agreed to invest $2 billion in Summit to accelerate development of ivonescimab, with the companies also set to evaluate ivonescimab alongside AstraZeneca's investigational Claudin-18.2-targeted ADC sonesitatug vedotin, or Sone-Ve, in gastrointestinal cancers. An FDA filing is under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment, with a final decision expected by Nov. 14, 2026.

Novo Nordisk is diversifying beyond its GLP-1 obesity and diabetes franchise, aiming to launch more than five potential blockbuster drugs by 2030 and generate over $23 billion in pipeline-related sales by 2035. The company, whose Ozempic and Wegovy have driven recent growth, has begun exploring the hair-loss market, which its Chief Scientific Officer says can leverage Novo's scientific knowledge, and plans to advance multiple Phase 3 programs across obesity, diabetes and other therapeutic areas. Chief Executive Mike Doustdar acknowledged the loss of confidence, saying it takes time and hard work to build back, after the company's post-Wegovy strategy presentation sent hair-loss drug developers Veradermics and Absci higher. Novo has lost ground to rival Lilly in the injectable GLP-1 market and faces key semaglutide patent expirations in major markets in the early 2030s, prompting Morgan Stanley to downgrade the stock to Sell on medium-term growth concerns. Novo trades at around 10.2x forward GAAP earnings, below its five-year average of 30.0x and the sector median of 23.3x, while its forward price-to-sales ratio of 3.8x is below its five-year average of 9.6x and broadly in line with the sector median of 3.7x.

Eli Lilly announced that the FDA has expanded the label of its oral cancer drug Jaypirca, also known as pirtobrutinib, to include a new indication in chronic lymphocytic leukemia or small lymphocytic lymphoma. Jaypirca has been approved to treat adults with previously untreated CLL/SLL who do not have a known 17p deletion, allowing the drug to be used as a first-line treatment for eligible patients. The approval is supported by data from the phase III BRUIN CLL-313 study, which showed that Jaypirca reduced the risk of disease progression or death by 80% compared to chemoimmunotherapy. Before this latest approval, Jaypirca was already approved for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor, and for adults with relapsed or refractory mantle cell lymphoma following two lines of systemic therapy including a BTK inhibitor. Jaypirca is already generating meaningful sales for Lilly, with revenues rising 66% year over year to $357 million in the first half of 2026, though its sales remain relatively small compared with Lilly's much larger obesity and diabetes portfolio.

Pacira BioSciences signed an exclusive agreement with Molteni Farmaceutici to distribute and commercialize EXPAREL in the European Union and U.K. Under the deal, Pacira will receive an undisclosed upfront payment, a supply price, and royalties on future commercial sales in the licensed territories. Pacira will continue to manufacture EXPAREL, while Molteni will oversee regulatory, market access, and commercialization activities. Molteni plans to launch EXPAREL sequentially in Italy, Germany, Austria, and Poland, with plans to seek approval in Switzerland. The first commercial sale is expected in 2027.

Shionogi & Co., Ltd. announced that its Board of Directors approved an agreement to acquire IntraBio Inc., a biopharmaceutical company developing and commercializing therapies for neurodegenerative diseases, for an upfront consideration of USD 2.0 billion payable to IntraBio shareholders. Under the agreement signed on October 5, 2026, IntraBio would become a wholly owned subsidiary of New Jersey-based Shionogi Inc., with the transaction scheduled to close between November 2026 and December 2026, subject to competition-law waiting periods and other customary conditions. The deal would add AQNEURSA (levacetylleucine) to Shionogi's rare disease portfolio; the drug was approved by the FDA in September 2024 for neurological manifestations of Niemann-Pick disease type C and by the European Medicines Agency in January 2026, and on September 18, 2026 it became the first and only FDA-approved treatment for Ataxia in patients with Ataxia-Telangiectasia, for which it is also under EMA review. Shionogi said the acquisition builds on the rare disease foundation it established through its April 2026 acquisition of global rights to edaravone, known as RADICAVA in the U.S. and RADICUT in Japan, and would strengthen its pipeline across Pompe disease, Fragile X syndrome, Jordan's syndrome and early-stage rare neurodegenerative programs. The impact on Shionogi's consolidated financial results for the fiscal year ending March 2027 is currently under review.

T. Man Pharmaceutical Public Company Limited, or TMAN, has announced the creation of a New S-Curve, moving into the longevity and wellness hub megatrend, with a target of driving revenue growth to 4 billion baht within the next 3-5 years, up from 2.5 billion baht in 2025. Prapol Thanachotiphan, Chief Executive Officer of TMAN, told InfoQuest that in the first 1-3 years the company will continue to grow from its core business by expanding hospital channels to raise their revenue share to 15-20% from 10% previously, while pushing the Propolis brand to become a full regional and international brand, from its current exports to more than 7 countries, and more than 10 countries across all products. Meanwhile, its OEM contract manufacturing business has grown by more than 100%, and it recently secured a major customer, Berham, in the distribution business for other brands. For the creation of the New S-Curve, the company will launch a new supplement brand at the end of this year, focusing on dietary supplements, vitamins and biotechnology under its own brand, targeting growth of 5-10% per year for this group over the next 5 years, and has assigned its subsidiary Nova Health to accelerate collaboration with leading research institutes to develop health innovations that address longevity, together with external partners.

Summit Therapeutics announced the closing of AstraZeneca's $2.0 billion strategic equity investment in the company. Under the Securities Purchase Agreement, AstraZeneca purchased approximately 108,955 shares of preferred stock convertible into Summit common stock at a 1:1,000 ratio, representing a common stock price of $18.36, a premium over the closing trading price on the day the investment was announced. The proceeds will support accelerated development of ivonescimab, a potential first-in-class investigational PD-1 / VEGF bispecific antibody, across solid tumor settings including combinations with antibody drug conjugates such as sonesitatug vedotin and Datroway. Summit Chairman and Co-Chief Executive Officer Robert W. Duggan said the investment reflects AstraZeneca's confidence in Summit and in ivonescimab's potential to redefine cancer treatment. Baker Hostetler LLP is serving as legal advisor to Summit.

Shionogi announced on the 5th that it will acquire US biopharmaceutical venture IntraBio. It will acquire all shares for 2 billion dollars, or about 316 billion yen, making it a wholly owned subsidiary. IntraBio was founded in 2015 and has strengths in the research and development of rare neurological disease drugs, with sales of 67.86 million dollars for the fiscal year ending December 2025. Shionogi is working to strengthen its rare disease drug business as a priority area outside of infectious diseases, and since April of this year it has begun global sales of a treatment for amyotrophic lateral sclerosis (ALS).

AnnJi Pharmaceutical announced it is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial of AJ201, also known as rosolutamide, in patients with spinal and bulbar muscular atrophy, or SBMA, also called Kennedy's disease. The company said it submitted the Phase 3 protocol to the U.S. FDA under its active Investigational New Drug application and will now activate U.S. sites for the global trial. The ROMA-KD study is a global, multicenter, randomized, double-blind, placebo-controlled trial expected to enroll approximately 200 ambulatory patients with symptomatic SBMA worldwide, with the United States as a key region, and is intended to support potential global regulatory submissions. AJ201, an investigational oral small molecule and a potential first-in-class treatment for SBMA, has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation in both the United States and the European Union. AnnJi said the Phase 3 program builds on encouraging results from its completed Phase 2 study announced in May 2025, and the company also noted its SBMA Patient and Care Partner Advisory Council, first announced in collaboration with the Kennedy's Disease Association at the 2026 KDA International Patient and Scientific Conference.

AnnJi Pharmaceutical is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial of AJ201, also known as rosolutamide, in patients with spinal and bulbar muscular atrophy, or SBMA, also called Kennedy's disease. The company said it submitted the Phase 3 protocol to the U.S. FDA under its active Investigational New Drug application and will now activate U.S. sites for the global trial. ROMA-KD is a global, multicenter, randomized, double-blind, placebo-controlled study expected to enroll approximately 200 ambulatory patients with symptomatic SBMA worldwide, with the United States as a key region, and is intended to support potential global regulatory submissions. AJ201, an investigational oral small molecule and a potential first-in-class treatment for SBMA, has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation in both the United States and the European Union. The Phase 3 program builds on encouraging results from the completed Phase 2 study announced in May 2025, and AnnJi said it has also established an SBMA Patient and Care Partner Advisory Council in collaboration with the Kennedy's Disease Association.

Dashenlin held an online briefing on its 2026 interim results on September 30, addressing investor questions about negative investing and financing cash flows, convertible bond conversion, and logistics and distribution. The company said the negative investing cash flow mainly stemmed from capital expenditure on new store openings, digitalisation and logistics system construction, as well as consideration paid for pharmacy acquisitions, while the negative financing cash flow was mainly due to continued cash dividends. Operating cash flow remained a net inflow. The 1.405 billion yuan convertible bonds issued by the company will mature on October 21, 2026, and have not yet been converted. The company said its cash reserves are sufficient, and it will assist holders willing to convert, while repaying principal and interest in full and on time to holders who hold to maturity, with controllable redemption risk. On logistics, the company has built a three-tier warehouse network of group warehouses, regional warehouses and district warehouses. As of the end of the reporting period, it had 35 warehouses nationwide, including in Inner Mongolia and Xinjiang, with total warehousing area of 420,000 square metres. Self-operated delivery accounted for more than 85% of total delivery volume, warehouse shipment fulfilment rate reached 99%, and shipment error rate was below 0.008%. The interim report showed revenue of 13.99 billion yuan, up 3.46% year on year; net profit attributable to the parent of 927 million yuan, up 16.10%; non-GAAP net profit attributable to the parent of 931 million yuan, up 18.05%; net operating cash flow of 1.289 billion yuan, down 55.70%; and a proposed cash dividend of 0.41 yuan per share before tax.

A Delaware federal judge on Monday rejected requests from Pfizer, BioNTech and Moderna to dismiss lawsuits filed by Bayer's Monsanto unit over their use of US Patent No. 7,741,118, a patent related to mRNA technology, with Judge William Bryson saying the companies failed to prove the patent was invalid or not infringed by their COVID-19 vaccines. Sanofi agreed to a deal worth up to $8B, including $1B upfront, with Regeneron to jointly develop four long-acting immunology therapies, led by the clinical-stage IL-13 monoclonal antibody REGN20423. China's Abogen Biosciences signed a licensing and option agreement with Novartis worth up to $7.8B, comprising a $575 million upfront payment and up to approximately $7.2 billion in potential milestone payments if all options on all programs are exercised, covering an exclusive worldwide license to Abogen's lead asset ABO2203. Jiangsu Hengrui Pharmaceuticals agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6B, with $300M upfront and the transaction expected to close in Q4 2026. Meanwhile, the S&P 500 Health Care Sector Index slipped 2.66% for the week, with Incyte down 6.93% and Regeneron down 6.71% among the top decliners, while McKesson rose 4.11% and Cardinal Health gained 3.67%.

CanSino surged to the daily limit up on the last trading day before the National Day holiday, with its share price breaking through the previous consolidation range and reaching a new stage high since April 2023, while its H shares also moved higher in tandem. On October 1, CanSino issued a stock movement announcement stating that the company had noted recent market developments regarding mRNA technology, as well as the release or planned disclosure of overseas clinical stage data for mRNA cancer vaccines. CanSino made clear that the mRNA platform is one of the technology platforms in its portfolio, and that the company is developing preventive mRNA vaccines and therapeutic biologics, as well as related delivery systems. In the therapeutic area, it is advancing research and development of mRNA vaccines for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of In Vivo CAR-related therapies, all of which are currently in early stages. In August this year, Merck and Moderna jointly announced that their personalized messenger RNA cancer vaccine met its primary endpoint in a Phase III trial, making it the first therapeutic vaccine proven effective in a large-scale Phase III clinical trial globally. On August 25, CanSino's official WeChat account announced that its subsidiary CanSino Shanghai Biologics had formally signed a strategic cooperation framework agreement with Depush Hangzhou Biotechnology for the joint development of personalized therapeutic mRNA cancer vaccines. The two parties will jointly advance the research, development, and commercialization of personalized therapeutic mRNA cancer vaccines, with a global focus on gastrointestinal solid tumors and rare tumor treatment areas. It should be noted that CanSino's entire mRNA product line has not yet moved beyond the early research and development stage, and innovative drug development carries multiple uncertainties including technical failure, clinical results falling short of expectations, and approval delays, while competition in the domestic mRNA vaccine sector is also becoming increasingly intense.

Johnson & Johnson reported new Phase 3 results for its oral peptide ICOTYDE in plaque psoriasis at the 2026 EADV Congress, showing sustained skin clearance and improvement across multiple high-impact psoriasis sites, including in adolescent patients. Long-term data from the ICONIC-TOTAL study showed sustained skin clearance through Week 112 at high-impact sites such as the scalp, genital area, hands, feet and nails. The oral IL-23 inhibitor remains in clinical studies for other major inflammatory diseases beyond plaque psoriasis, including psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE is already approved in the U.S., Europe, Japan and China, and the key test ahead is how the evidence translates into prescribing and reimbursement decisions in those markets. Johnson & Johnson is a global healthcare group that develops prescription drugs, medical devices and consumer health products.

AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics announced clinical collaboration agreements to test ivonescimab in combination with Datroway and sonesitatug vedotin across multiple tumour types, starting with a planned Phase III trial in first-line triple-negative breast cancer and gastrointestinal cancer. AstraZeneca's approximately US$2.00 billion equity investment via convertible preferred stock, alongside the co-funded oncology trials, prices the preferred stock at an implied US$18.36 per common share and targets roughly a 12% ownership stake in Summit. All parties retain full rights to their respective medicines. The investment strengthens Summit's funding and combination profile ahead of the HARMONi and HARMONi-3 readouts, though the U.S. FDA decision on the HARMONi BLA remains the key near-term catalyst and central source of risk. Summit's narrative projects $1.3 billion revenue and $223.0 million earnings by 2029, while some optimistic analysts model about US$2.7 billion of revenue and nearly US$289 million of earnings by 2029.

Merck reported positive Phase 2b results for tulisokibart in moderate to severe hidradenitis suppurativa on 1 October 2026. The investigational anti TL1A monoclonal antibody met its Phase 2b efficacy goals in patients with this chronic inflammatory skin condition, and Merck stated that the data support advancing the program into Phase 3 trials in hidradenitis suppurativa. The company said the readout backs the idea that tulisokibart can anchor a new immunology franchise rather than patch a niche condition, helping Merck argue it is building multiple disease-area pillars next to oncology, in contrast to peers like AbbVie and Johnson & Johnson that already lean heavily on immunology blocks. The bear case is that one successful readout does not erase execution risk across the rest of the late stage portfolio, especially with analysts already flagging profit margin pressure and safety questions on assets such as remigromig. Merck is a global healthcare group headquartered in GB that develops medicines across multiple disease areas.

Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio. The project builds on more than seven billion dollars in U.S. pharma research, development and manufacturing spend over the past five years and is a central element of Bayer's long-term growth strategy in its largest pharmaceuticals market. Bayer expects to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs during the facility's construction. The flexible, modular campus will combine drug substance and drug product manufacturing and initially support Bayer's growing portfolio in oncology, cardiovascular and renal care, with the first drug substance module expected to become operational in 2031 and a second drug product module planned for 2034. The new site will complement Bayer's U.S. pharmaceuticals headquarters in Whippany, New Jersey, and its other sites in Pittsburgh, Berkeley, Cambridge, Research Triangle Park and San Diego.

Bayer will invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio, a project announced by Ohio Governor Mike DeWine alongside the company and JobsOhio. The site is expected to create around 600 high-value jobs in the New Albany International Business Park and roughly 1,500 construction jobs, with the first module dedicated to drug substance manufacturing set to become operational in 2031 and a second drug product module planned for 2034. Bayer CEO Bill Anderson said the flexible, modular campus will support the company's growing portfolio in oncology, cardiovascular and renal care, building on more than $7 billion in U.S. pharma R&D and manufacturing spending over the past five years. Workforce readiness was central to Ohio's appeal, with Bayer drawing on the Ohio Life Science Training Center, under construction and scheduled to open in summer 2027, to which JobsOhio is contributing up to $30 million alongside nearly $8 million from the City of New Albany, the State of Ohio and The New Albany Company. The project will pursue a Job Creation Tax Credit from the Ohio Department of Development at a future Tax Credit Authority meeting, and Bayer also plans to pursue JobsOhio assistance that would be made public after a final agreement is executed.

Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved an expanded indication for Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion, allowing use as a first-line therapy. The approval is based on the primary analysis of the Phase 3 BRUIN CLL-313 trial, the first prospective, randomized Phase 3 study to examine a non-covalent BTK inhibitor in previously untreated CLL/SLL without 17p deletion, which enrolled 282 patients randomized 1:1 to pirtobrutinib or bendamustine plus rituximab. At a median follow-up of 28 months, Independent Review Committee-assessed progression-free survival was significantly improved with pirtobrutinib versus bendamustine plus rituximab (HR=0.20 [95% CI, 0.11–0.37]; p<0.0001), with median PFS not yet reached for pirtobrutinib compared to 33.5 months for bendamustine plus rituximab, while IRC-assessed overall response rate was 94% (95% CI, 89–98) for pirtobrutinib versus 81% (95% CI, 73–87) for the comparator. In the trial, adverse reactions led to dose reductions in 3.6% and permanent discontinuation of Jaypirca in 4.3% of patients, with serious adverse reactions in 28% of those receiving the drug. Jaypirca is the first-and-only non-covalent BTK inhibitor recommended by the National Comprehensive Cancer Network, holding a Category 2A recommendation for treatment-naïve adult CLL/SLL patients without del(17p) and a Category 1 preferred option for relapsed or refractory patients previously treated with a covalent BTK inhibitor.

Pfizer reported that its oral drug LITFULO significantly improved facial and total body repigmentation in adults with nonsegmental vitiligo across two Phase 3 trials, and said it intends to submit the data to regulators globally, including the U.S. Food and Drug Administration and the European Medicines Agency. In the TRANQUILLO 2 study of 100 mg LITFULO and the TRANQUILLO study of 50 mg LITFULO, 21.86% and 12.47% of patients achieved F-VASI75, a 75% or greater improvement in the Facial Vitiligo Area Scoring Index, compared with 2.40% and 2.48% on placebo, while 13.02% and 8.98% achieved T-VASI50, a 50% or greater improvement in the Total Vitiligo Area Scoring Index, compared with 2.40% and 1.98% on placebo. Improvements began as early as Week 24 and increased through Week 36 and Week 52, and LITFULO also reduced patient-reported facial and overall disease severity at Week 52. The Phase 3 TRANQUILLO program, the largest to date evaluating an oral systemic therapy for nonsegmental vitiligo, enrolled 2,174 patients across 271 sites worldwide, with TRANQUILLO 2 testing 100 mg once daily in 1,567 adults and TRANQUILLO testing 50 mg once daily in 607 patients aged 12 years and older. The safety profile was consistent with that established in alopecia areata, with no new safety signals; treatment-emergent adverse events occurred in 67.7% of patients on LITFULO 100 mg versus 62.0% on placebo in TRANQUILLO 2, and in 81.0% versus 77.1% in TRANQUILLO. The results were presented in a late-breaking oral presentation at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria.

Sanofi and Regeneron Pharmaceuticals have expanded their longstanding antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation. Under the agreement, the companies will co-develop and co-commercialize four Regeneron-invented antibodies targeting IL-13, an IL-4xIL-13 bispecific, IL-4 and IL-4Rα, with one program, REGN20423, a long-acting IL-13 monoclonal antibody, currently in a phase I study for atopic dermatitis and the other three expected to enter clinical studies in 2027. Regeneron is entitled to a $1 billion upfront payment from Sanofi and up to $7 billion in additional development, regulatory and commercial milestone payments, while the two will equally share development and commercialization costs and future profits globally, with Regeneron leading research and development and Sanofi overseeing global commercial efforts. Regeneron will also have an option to include Sanofi's investigational candidate lunsekimig, a bispecific nanobody therapy targeting TSLP and IL-13, in the collaboration after completion of its phase III studies in chronic obstructive pulmonary disease, and the companies agreed to settle their prior collaboration-related litigation. The expanded collaboration builds on a more than 20-year alliance that established Dupixent as a widely used treatment for type II inflammation, with more than 1.5 million people currently receiving the drug across nine indications, and the existing profit-sharing agreement for Dupixent will remain unchanged.

AstraZeneca agreed to invest about US$2 billion in Summit Therapeutics through convertible preferred stock and entered a non exclusive clinical collaboration built around ivonescimab combinations. The deal gives Summit Therapeutics a US$2 billion partner-backed runway, with the company's share price still below AstraZeneca's implied US$18.36 entry. Summit Therapeutics' share price has been volatile, with a 6.9% 7 day share price return and a 14.3% 30 day share price return, while the year to date share price return is down 4.7% and the 1 year total shareholder return has declined 22.1%. On the most followed narrative, Summit Therapeutics screens as materially undervalued, with an implied fair value of about $29 per share versus the recent $16.69 close, putting the AstraZeneca deal, HARMONi data and the ivonescimab franchise at the center of the debate over how far the rerating can go. The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, though the company carries real event risk with a single lead asset, heavy R&D spend, and key HARMONi and FDA decisions that could challenge the bullish thesis.

Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTAL study showing that ICOTYDE (icotrokinra), its targeted oral peptide that blocks the IL-23 receptor, delivered sustained skin clearance in patients with difficult-to-treat plaque psoriasis affecting high-impact sites. The late-breaking results, presented at the European Academy of Dermatology and Venereology Congress 2026, showed that rates of clear or almost clear skin among ICOTYDE-treated patients rose from 57% at Week 16 to 67% at Week 24 and 70% at Week 112. At Week 112, 60% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment score of 0, 89% of patients with genital psoriasis achieved a Physician's Global Assessment of Genitalia score of 0, and 63% of patients with psoriasis affecting the hands and/or feet achieved a hand and/or foot Physician's Global Assessment score of 0. Mean percentage improvement in the modified Nail Psoriasis Severity Index increased from 33% at Week 16 to 62% at Week 52 and 71% at Week 112, and safety findings through Week 112 remained consistent with the established safety profile of ICOTYDE, with no new safety signals identified. ICOTYDE is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older weighing at least 40 kg, and is also approved in Europe, Japan and China; it was jointly discovered and is being developed under a license and collaboration agreement between Protagonist and Johnson & Johnson.

Novartis has entered into a licensing and option agreement with China's Abogen Biosciences to advance RNA-encoded therapeutics, according to a statement on Friday. Abogen will receive an upfront payment of $575 million, and, if all options on all programs are exercised, Abogen is eligible to receive up to approximately $7.2 billion in potential milestone payments, plus potential royalties on future product sales. The agreement includes an exclusive worldwide license to Abogen's lead asset, ABO2203, a novel mRNA-encoded CD19xCD3 T-cell engager designed to reset B cells by directing endogenous production of T-cell engagers in vivo, with the potential to transform treatment for patients with autoimmune diseases. The Swiss drugmaker also holds the exclusive option to license a number of next-generation therapeutic assets developed on Abogen's proprietary RNA platform.

AstraZeneca and Daiichi Sankyo have entered a clinical trial collaboration agreement with Summit Therapeutics to evaluate Datroway, also known as datopotamab deruxtecan, in combination with Summit's ivonescimab across multiple tumor types. The companies plan to begin with a phase 3 trial in first-line triple negative breast cancer. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. Under the agreement, each company will contribute its respective compound for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo. AstraZeneca, Daiichi Sankyo and Summit will each contribute to trial costs, and each company will retain development and commercial rights to its respective medicines.

Daiichi Sankyo and AstraZeneca have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway, or datopotamab deruxtecan, in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer. Under the terms of the agreement, each company will contribute their respective compound for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo, with all three companies contributing to trial costs and each retaining development and commercial rights to their respective medicines. Datroway is a TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca, while ivonescimab is a potential first-in-class bispecific antibody combining PD-1 blockade with anti-angiogenesis VEGF blockade. Daiichi Sankyo's John Tsai, AstraZeneca's Susan Galbraith and Summit's Maky Zanganeh all cited the combination's potential to deliver meaningful benefit across multiple tumor types, with Summit describing the collaboration as an expansion of its global development program into breast cancer.

Abogen Biosciences has entered a licensing and option agreement with Novartis to advance RNA-encoded therapeutics, including an exclusive worldwide license to Abogen's lead asset ABO2203. ABO2203 is a novel mRNA-encoded CD19xCD3 T-cell engager designed to reset B cells by directing endogenous production of T-cell engagers in vivo, and Abogen said it is the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. Under the agreement, Novartis also receives exclusive options to license a number of next-generation therapeutic assets developed on Abogen's RNA platform. Abogen will receive an upfront payment of USD 575 million and, if all options on all programs are exercised, is eligible for up to approximately USD 7.2 billion in potential milestone payments, plus potential royalties on future product sales. The transaction is subject to customary closing conditions, including required regulatory clearances.

Yuanta Securities issued an analysis turning more bullish on SINOBIO19, or the ordinary shares of SINO BIOPHARMACEUTICAL LIMITED (1177.HK), after the company announced a partnership with STADA, a global pharmaceutical company in Germany, to bring TQB3570, a biologic drug with efficacy close to that of Keytruda, the world's most popular cancer treatment, into the European, UK, and Swiss markets, with the potential to expand into the US market in the future. Under the deal, Sino Bio will manufacture and supply the drug itself but distribute it under STADA's brand, and will recognize a profit share of more than 10%. This means Sino Bio will recognize revenue from both manufacturing and an additional share of profits when STADA sells the drug in the region, creating a new revenue base for the company. Meanwhile, the Chinese government continues to target innovative pharmaceuticals as one of its key industries and will push for the sector to grow by an average of 20% per year during 2026-2030, giving the company the opportunity to receive government support both in speeding up approvals for drugs in its pipeline and in supporting R&D. As for this year's normalized profit outlook, the Bloomberg Consensus expects normalized profit to continue growing by 5%. The current price trades at a 2027 PER of 18 times. It gives a target price of 7.10 baht per DR, implying 44% upside.

French pharmaceutical giant Sanofi and U.S. biopharmaceutical company Regeneron Pharmaceuticals announced on the 1st that they will jointly develop four new drugs under a contract worth up to $8 billion and will settle their previous litigation. Sanofi will pay $1 billion upfront and an additional $7 billion upon achieving milestones. The two companies will split the development costs and future profits of the four new drugs, with Regeneron leading research and development and Sanofi handling global sales if the drugs are approved. The four new drugs include a candidate treatment for atopic dermatitis, which is currently in early-stage clinical trials. Sanofi's new Chief Executive Officer, Belén Garijo, said on an investor conference call that "mutual trust will guide this expanded partnership," adding that the partnership includes clear divisions of roles and accountability for both companies.

AstraZeneca PLC said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. and run joint trials of the two companies' cancer drugs. The money buys preferred shares convertible into common stock at an equivalent of $18.36 each, a premium to Summit's September 28 close of $15.48, and the conversion price buys roughly 109 million shares, or about 12% of the company once those shares exist. AstraZeneca is not acquiring Summit and is not licensing the drug outright; it is taking convertible preferred stock alongside a clinical collaboration to test Summit's ivonescimab with AstraZeneca's sonesitatug vedotin across several tumor types. The FDA has set a decision date of November 14 for ivonescimab's use in EGFR-mutant lung cancer, so AstraZeneca is buying in six weeks before an answer arrives, and Summit reported a loss of $1.11 a share over the past twelve months. AstraZeneca, worth about $262 billion, closed at $161.47 on September 30, while Summit opened above the $18.36 conversion price the morning after the announcement and closed well below it at $16.91.